Newsfeeds - Spark Newswire

3 minute read

Alnylam Pharmaceuticals Says CEO John Maraganore To Retire By End Of Year; Names Yvonne Greenstreet As New CEO

Today, 5:06 PM

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, MBChB, at year-end 2021. Dr.

ALNY

19 minute read

Earnings Scheduled For October 28, 2021

By Benzinga Insights

Today, 5:06 PM

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.

AAPL

4 minute read

FDA
News

Alnylam Reports Topline 18-Month Results From HELIOS-A Phase 3 Study Of Vutrisiran In Patients With hATTR Amyloidosis With Polyneuropathy

By Benzinga Newsdesk

Today, 5:06 PM

– Vutrisiran Met All 18-Month Secondary Endpoints, Including Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), Gait Speed, Nutritional Status and Overall Disability,

ALNY

4 minute read

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More

By Shanthi Rexaline

Today, 5:06 PM

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

ABBV

2 minute read

Alnylam Pharma Reports Received Positive Reimbursement Recommendation From Canadian Agencies For Drugs And Technology In Health For Use Of GIVLAARI As Treatment Of Acute Hepatic Prophyria

By Benzinga Newsdesk

Today, 5:06 PM

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is pleased to announce that GIVLAARI® (givosiran) has now received a positive recommendation for reimbursement from the Canadian Agency for Drugs and

ALNY

1 minute read

Analyst Ratings

Where Alnylam Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 5:06 PM

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

ALNY

1 minute read

Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $242

By Benzinga Newsdesk

Today, 5:06 PM

Morgan Stanley analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $234 to $242.

ALNY

4 minute read

10 Health Care Stocks With Unusual Options Alerts In Today’s Session

By Benzinga Insights

Today, 5:06 PM

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.

ABBV

2 minute read

Analyst Ratings

Analyst Ratings For Alnylam Pharmaceuticals

By Benzinga Insights

Today, 5:06 PM

Over the past 3 months, 7 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

ALNY

1 minute read

UBS Upgrades Alnylam Pharmaceuticals to Buy, Raises Price Target to $215

By vishwanath@benzinga.com

Today, 5:06 PM

UBS analyst Esther Rajavelu upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Neutral to Buy and raises the price target from $141 to $215.

ALNY